Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Definitive Healthcare (DH) Gains from Sales and Divestitures (2022 - 2025)

Definitive Healthcare filings provide 4 years of Gains from Sales and Divestitures readings, the most recent being $3.9 million for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 724.3% to $3.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 724.3% increase, with the full-year FY2025 number at $3.9 million, up 724.3% from a year prior.
  • Gains from Sales and Divestitures hit $3.9 million in Q4 2025 for Definitive Healthcare, up from $478010.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $3.9 million in Q4 2025 to a low of $96191.0 in Q1 2022.
  • Median Gains from Sales and Divestitures over the past 4 years was $716776.0 (2022), compared with a mean of $1.0 million.
  • Biggest five-year swings in Gains from Sales and Divestitures: tumbled 40.7% in 2024 and later skyrocketed 724.3% in 2025.
  • Definitive Healthcare's Gains from Sales and Divestitures stood at $716776.0 in 2022, then increased by 12.47% to $806128.0 in 2023, then tumbled by 40.7% to $478010.0 in 2024, then skyrocketed by 724.3% to $3.9 million in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $3.9 million (Q4 2025), $478010.0 (Q4 2024), and $806128.0 (Q4 2023) per Business Quant data.